Cyclopropane-Annelated Azaoligoheterocycles by Ti-Mediated Intramolecular Reductive Cyclopropanation of Cyclic Amino Acid Amides

Total Synthesis of Sarpagine Alkaloid (-)-Normacusine B

An asymmetric total synthesis of the sarpagine alkaloid (-)-normacusine B is presented. Salient features of this synthesis include a photocatalytic nitrogen-centered radical cascade reaction to assemble the tetrahydrocarbolinone skeleton, a titanium-mediated intramolecular amide-alkene coupling to construct the bridged azabicyclo[3.3.1]nonane moiety, and a nickel-catalyzed reductive Heck coupling to assemble the azabicyclo[2.2.2]octane ring system.

Facile ring-opening of azabicyclic [3.1.0]- and [4.1.0]aminocyclopropanes to afford 3-piperidinone and 3-azepinone

Azabicyclic [3.1.0] and [4.1.0] Kulinkovich products underwent a facile reduction/fragmentation to afford a variety of 3-piperidinones and 3-azepinones, respectively, in the presence of catalytic palladium on carbon and formic acid in an atmosphere of hydrogen.

Synthesis of conformationally locked carbocyclic nucleoside phosphonates to probe the active site of HIV-1 RT

The conformationally locked carbocyclic nucleoside phosphonates 2 and 2' and key intermediates for the synthesis of 3 and 3' were prepared from a chiral cyclopentene derivative and epicholorohydrine, respectively. The structure of the nucleoside precursor 6 was confirmed by X-ray crystallography. These carbocyclic nucleoside phosphonates were designed to probe their binding interactions at the active site of HIV-1-RT.

One-Step Synthesis of Heteroaromatic-Fused Pyrrolidines via Cyclopropane Ring-Opening Reaction: Application to the PKCβ Inhibitor JTT-010

A ring-opening reaction of cyclopropanes with five-membered heteroaromatics having a leaving group at C(2) was found to provide heteroaromatic-fused pyrrolidines in one step. This reaction was successfully applied to the synthesis of the protein kinase C-beta inhibitor JTT-010, which possesses a dihydropyrrolo[1,2-a]indole core.

An Access to 3,4-(Aminomethano)proline in Racemic and Enantiomerically Pure Form

Protected racemic and enantiomerically pure 3,4-(aminomethano)prolines rac-9 and (2S,2'R,3R,4R)-9 have been prepared applying a titanium-mediated reductive cyclopropanation as a key step. Thus, cyclopropanations of N,N-dibenzylformamide with titanacyclopropanes generated in situ from racemic or enantiomerically pure tert-butyl N-Boc-3,4-dehydroprolinates rac-8 or (S)-8 proceed diastereoselectively, and furnish the protected racemic and enantiomerically pure diamino acid 9. The latter was incorporated into three tripeptides containing glycyl, alanyl and phenylalanyl moieties.

Novel Ruthenium-Based Metathesis Catalysts Containing Electron- Withdrawing Ligands: Synthesis, Immobilization, and Reactivity

The syntheses and reactivity of seven different ruthenium-based metathesis catalysts are described. Ru(CF3COO)2(PCy3)(=CH-2-(2-PrO)C6H4) (1), Ru(CF3COO)2(1,3-dimesityldihydroimidazolin-2-ylidene)(=CH-2-(2-PrO)C6H4) (2), and Ru(CF3COO)2(PCy(3))(1,3-dimesityldihydroimidazolin-2-ylidene)(=CHC6H5) (3) were prepared via chlorine exchange by reacting RuCl2(PCy3)2(=CH-2-(2-PrO)C6H4), RuCl2(1,3-dimesityldihydroimidazolin-2-ylidene)(=CH-2-(2-PrO)C6H4), and RuCl2(PCy3)(1,3-dimesityldihydroimidazolin-2-ylidene)(=CHC6H5), respectively, with silver trifluoroacetate (Cy =cyclohexyl). In analogy, Ru(CF3CF2COO)2(1,3-dimesityldihydroimidazolin-2-ylidene)(=CH-2-(2-PrO)C6H4) (4) and Ru(CF3CF2CF2COO)2(1,3-dimesityldihydroimidazolin-2-ylidene)(=CH-2-(2-PrO)C6H4) (5) were prepared from RuCl2(1,3-dimesityldihydroimidazolin-2-ylidene)(=CH-2-(2-PrO)C6H4) via reaction with CF3CF2COOAg and CF3CF2CF2COOAg, respectively. Ru(C6F5COO)2(1,3-dimesityldihydroimidazolin-2-ylidene)(=CH-2-(2-PrO)C6H4) (6) and Ru(C6F5O)2(1,3-dimesityldihydroimidazolin-2-ylidene)(=CH-2-(2-PrO)C6H4) (7) were prepared from RuCl2(1,3-dimesityldihydroimidazolin-2-ylidene)(=CH-2-(2-PrO)C6H4) via reaction with C6F5COOTl and C6F5OTl, respectively. Supported catalysts Ru(PS-DVB-CH2OOCCF2CF2CF2COO)(CF3COO)(PCy3)(1,3-dimesityldihydroimidazolin-2-ylidene)(=CHC6H5) (8), Ru(PS-DVB-CH2OOCCF2CF2CF2COO)(CF3COO)(PCy3)(=CH-2-(2-PrO)C6H4) (9), and Ru(PS-DVB-CH2OOCCF2CF2CF2COO)(CF3COO)(1,3-dimesityldihydroimidazolin-2-ylidene)(=CH-2-(2-PrO)C6H4) (10) were synthesized by reaction of RuCl2(PCy3)(1,3-dimesityldihydroimidazolin-2-ylidene)(=CHC6H5), RuCl2(PCy3)(=CH-2-(2-PrO)C6H4), and RuCl2(1,3-dimesityldihydroimidazolin-2-ylidene)(=CH-2-(2-PrO)C6H4), respectively, with a perfluoroglutaric acid-derivatized poly(styrene-co-divinylbenzene) (PS-DVB) support (silver form). Halogen exchange in PCy3-containing systems had to be carried out in dichloromethane in order to suppress precipitation of AgCl.PCy3. The reactivity of all new catalysts in ring-closing metathesis (RCM) of hindered electron-rich and -poor substrates, respectively, at elevated temperature (45 degrees C) was compared with that of existing systems. Diethyl diallylmalonate (DEDAM, 11), diethyl allyl(2-methylallyl)malonate (12), N,N-diallyl-p-toluenesulfonamide (13), N-benzyl-N-but-1-en-4-ylbut-2-enecarboxylic amide (14), and N-allyl-N-(1-carboxymethyl)but-3-en-1-yl-p-toluenesulfonamide (15) were used as educts. Supported catalysts were prepared with high loadings (2.4, 22.1, and 160 mg of catalyst/g PS-DVB for 8, 9, and 10, respectively). Catalyst 8 showed higher and catalysts 9 and 10 sowed significantly reduced activities in RCM compared to their homogeneous analogues. Thus, with 8, turnover numbers (TONs) up to 4200 were realized in stirred-batch (carousel) RCM experiments. To elucidate the nature of the bound species, catalysts 8-10 were subjected to 13C- and 31P-MAS NMR spectroscopy. These investigations provided evidence for the proposed structures. Leaching of ruthenium into the reaction mixture was low, resulting in ruthenium contents <85 ppb (ng/g) in the final RCM-derived products.